Examines the Historical and Forecast Performance for UCB S.A.: Financial News

Examines the Historical and Forecast Performance for UCB S.A.
Monday October 6, 2008 7:41 am ET

LONDON, UNITED KINGDOM--(MARKET WIRE)--Oct 6, 2008 -- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

UCB S.A.: PharmaVitae Profile

http://www.reportlinker.com/p095769/UCB-SA-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

- Benchmark UCB's performance against key rivals in the ethical pharmaceutical sector

- Assess how M&A has shaped UCB into a next generation bio-pharmaceutical player

- Assess UCB's market leading position in the epilepsy treatment segment and the use of life cycle management in a bid to retain this status

 

CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 6
UCB: PharmaVitae forecasts at a glance 7
Strategic insight 8
Overview of UCB's corporate evolution 8
High expecations for AED franchise despite Keppra generics 11
Keppra generic defense strategy key to maintaining sales position 11
Vimpat and Rikelta set to form a next-generation AED franchise 13
Biopharmaceutical business model yet to deliver sales growth 14
SWOT analysis 17
Strengths 17
Weaknesses 19
Opportunities 20
Threats 20
CHAPTER 3 QUARTERLY NEWS UPDATE 25
Product developments 25
Deals and alliances 26
Product deals 26
Technology deals 26
M&A activity 27
Company announcements 28
Future product milestones 29
CHAPTER 4 COMPANY INTRODUCTION 30
Key findings 30
Background 31
Key corporate developments 31
M&A history 33
Celltech 33
Schwarz Pharma 34
M&A strategy 35
Current corporate structure 35
CHAPTER 5 COMPANY SALES 36
Key findings 36
Prescription pharmaceutical sales and growth rate analysis, 2001-13 38
Historical analysis 39
Forecast analysis 40
Product analysis 41
Product analysis, 2001-07 42
Growth drivers 43
Growth resistors 44
Product analysis, 2007-13 45
Growth drivers 46
Growth resistors 47
Therapy area analysis 49
Therapy area analysis, 2001-07 51
Therapy area analysis, 2007-13 53
Therapy area focus, 2001-13 57
Geographic analysis 59
Geographic analysis, 2001-07 60
Geographic analysis, 2007-13 61
Geographic focus, 2001-13 63
Launch/core/expiry analysis 64
Explanation of launch/core/expiry analysis 64
Launch analysis, 2007-13 65
Core analysis, 2007-13 67
Expiry analysis, 2007-13 68
Launch/core/expiry configuration, 2007-13 70
Molecule type analysis 71
Molecule type analysis, 2001-07 72
Molecule type analysis, 2007-13 72
Externalization analysis 74
Externalization analysis, 2001-07 75
Externalization analysis, 2007-13 76
CHAPTER 6 COMPANY FINANCIALS 79
Key findings 79
Reconciliation between PharmaVitae-formatted prescription pharma sales and
company-reported total sales, 2001-07 81
Financial statements, 2001-07 83
Profit and loss account, 2001-07 83
Balance sheet, 2001-07 85
Operating costs and profit analysis 87
Operating costs and profit analysis, 2001-07 88
Operating cost ratio and profit margin analysis, 2001-07 89
Operating cost ratio and profit margin analysis, 2007-13 91
Operating costs and profit analysis, 2007-13 93
Return on capital employed analysis 94
Capital employed analysis, 2001-07 95
Return on capital employed (RoCE) analysis, 2001-07 97
Market capitalization analysis 100
Market capitalization analysis, 2001-07 100
Total shareholder returns analysis, 2001-07 101
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 103
Key findings 103
Overview 105
Central nervous system 106
Keppra 106
Overview 107
Sales forecast 108
Vimpat 113
Overview 114
Sales forecast 115
Neupro 119
Overview 120
Sales forecast 121
Rikelta 126
Overview 127
Sales forecast 128
Immunology & inflammation 130
Cimzia 130
Overview 131
Sales forecast 132
Respiratory 135
Xyzal 135
Overview 136
Sales forecast 137
CHAPTER 8 APPENDIX 139
R&D pipeline 139
References 140
Abbreviations 140
Exchange rates 142
List of Tables
Table 1: UCB - PharmaVitae forecasts at a glance 7
Table 2: UCB key product developments, Q1&2 2008 25
Table 3: UCB product deals and alliances, Q1&2 2008 26
Table 4: UCB technology deals and alliances, Q1&2 2008 26
Table 5: UCB M&A activity, Q1&2 2008 27
Table 6: UCB company announcements, Q1&2 2008 28
Table 7: UCB future product milestones, 2008-09 29
Table 8: UCB product portfolio overview ($m), 2001-07 42
Table 9: UCB product portfolio overview ($m), 2007-13 45
Table 10: UCB product portfolio overview ($m), 2001-07 51
Table 11: UCB product portfolio overview ($m), 2007-13 53
Table 12: UCB portfolio overview by geographic region ($m), 2001-07 60
Table 13: UCB portfolio overview by geographic region ($m), 2007-13 61
Table 14: UCB launch portfolio overview ($m), 2007-13 65
Table 15: UCB core portfolio overview ($m), 2007-13 67
Table 16: UCB expiry portfolio overview ($m), 2007-13 68
Table 17: UCB portfolio overview by molecule type ($m), 2001-07 72
Table 18: UCB product portfolio overview by molecule type ($m), 2007-13 72
Table 19: UCB product portfolio overview by source ($m), 2001-07 75
Table 20: UCB product portfolio overview by source ($m), 2007-13 76
Table 21: Total UCB sales by business unit ($m), 2001-07 81
Table 22: UCB profit and loss account ($m), 2001-07 83
Table 23: UCB balance sheet ($m), 2001-07 85
Table 24: UCB operating revenue/cost analysis ($m), 2001-07 88
Table 25: UCB operating cost ratio analysis (% of total revenues),
2001-07 89
Table 26: UCB operating cost ratio analysis (% of total revenues),
2007-13 91
Table 27: UCB operating revenue/cost analysis ($m), 2007-13 93
Table 28: UCB capital employed ($m), 2001-07 95
Table 29: UCB EBIT return on capital employed ($m), 2001-07 97
Table 30: UCB EBIT pre-tax return/capital employed driver analysis (%),
2001-07 98
Table 31: UCB market capitalization ($ billion), 2001-07 100
Table 32: UCB total shareholder returns (annual %), 2001-07 101
Table 33: Key products overview 105
Table 34: Keppra: overview 107
Table 35: Keppra: sales forecast ($m), 2007-13 108
Table 36: Vimpat: overview 114
Table 37: Vimpat: sales forecast ($m), 2007-13 115
Table 38: Neupro: overview 120
Table 39: Neupro: sales forecast ($m), 2007-13 121
Table 40: Rikelta: overview 127
Table 41: Rikelta: sales forecast ($m), 2007-13 128
Table 42: Cimzia: overview 131
Table 43: Cimzia: sales forecast ($m), 2007-13 132
Table 44: Xyzal: overview 136
Table 45: Xyzal: sales forecast ($m), 2007-13 137
Table 46: UCB's R&D pipeline (Phase I-registration) 139
Table 47: Exchange rates, 2007 142
List of Figures
Figure 1: UCB prescription pharmaceutical performance, sales ($m) and
growth rate (%), 2001-13 5
Figure 2: UCB's financial performance ($m), 2001-13 6
Figure 3: UCB business model transformed by M&A 8
Figure 4: Sales of UCB's AED portfolio ($m), 2007-13 11
Figure 5: UCB SWOT analysis 17
Figure 6: UCB prescription pharmaceutical performance, sales ($m) and
growth rate (%), 2001-13 38
Figure 7: UCB key sales growth driver & resistors ($m), 2001-07 43
Figure 8: UCB key sales growth drivers & resistors ($m), 2007-13 46
Figure 9: UCB prescription pharmaceutical sales by therapy area ($m),
2001-13 49
Figure 10: UCB prescription pharma sales by therapy area (% of total),
2001-13 57
Figure 11: UCB prescription pharmaceutical sales by geographic region ($m),
2001-13 59
Figure 12: UCB growth drivers and resistors by geographic region ($m),
2001-07 60
Figure 13: UCB drivers and resistors by geographic region ($m), 2007-13 62
Figure 14: UCB prescription pharmaceutical sales by geographic region (% of
total), 2001-13 63
Figure 15: UCB launch/core/expiry configuration ($m), 2007-13 70
Figure 16: UCB prescription pharmaceutical sales by molecule type ($m),
2001-13 71
Figure 17: UCB growth drivers and resistors by molecule type ($m),
2007-13 73
Figure 18: UCB prescription pharmaceutical sales by source ($m), 2001-13 74
Figure 19: UCB growth drivers and resistors by source ($m), 2007-13 77
Figure 20: UCB operating revenue/cost analysis ($m), 2001-13 87
Figure 21: UCB operating cost ratio analysis (% of total revenues),
2001-13 92
Figure 22: UCB return on capital employed, EBIT margin and capital
turnover, 2001-07 94
Figure 23: Return on capital employed formula 98
Figure 24: UCB market capitalization ($ billion), 2001-07 101
Figure 25: UCB total shareholder returns vs. S&P 500 ($m), 2001-07 102

To order this report:

UCB S.A.: PharmaVitae Profile

http://www.reportlinker.com/p095769/UCB-SA-PharmaVitae-Profile.html

More market research reports here!